2-(吗啉-4-甲基)苯胺 | 95539-61-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(吗啉-4-甲基)苯胺
• 中文别名: 2-(吗啉-4-基甲基)苯胺；2-吗啉甲基苯胺
• 英文名称: 1-amino-2-(N-morpholinomethyl)benzene
• 英文别名: 2-(morpholin-4-ylmethyl)aniline；2-(morpholinomethyl)aniline；4-(o-aminobenzyl)morpholine；(4-morpholinylmethyl)aniline；4-(2-aminobenzyl)morpholine；2-morpholinomethyl-aniline
• CAS: 95539-61-0
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD04114505
• 分子量: 192.261
• InChiKey: BNBJMXCRCHPDIG-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C
• 沸点：
  150-152 °C(Press: 4 Torr)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(吗啉-4-甲基)苯胺 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 2-(morpholin-4-ylmethyl)-N-[(4-phenylphenyl)methyl]aniline
  参考文献：
  名称：

  Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives

  摘要：

  Novel toluidine derivatives are described. Some of them showed an interesting in vitro activity against Mycobacterium tuberculosis, M. smegmatis, M. marinum, M. gordonae, and M. avium. Some of them were more active than Streptomycin and Isoniazid, which were used as controls, against M. avium and M. gordonae. In particular, we confirm the good activity of biphenyl derivatives. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00084-1
• 作为产物：
  描述：

  2-硝基苄溴 在 hydrazine hydrate 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 4.33h， 生成 2-(吗啉-4-甲基)苯胺
  参考文献：
  名称：

  Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

  摘要：

  Receptor tyrosine kinase PDGFR alpha is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFR alpha and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFR alpha and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFR alpha and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFR alpha signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111663

文献信息

• Amidine derivatives with nitric oxide synthetase activities
  申请人：Astra Aktiebolag

  公开号：US05807885A1

  公开（公告）日：1998-09-15

  Amidine derivative compounds of formula I as defined in the Specification having nitric oxide synthetase inhibitory activity as well as processes for the preparation of and compositions containing said compounds are described.

  根据说明书定义的I公式酰胺衍生物化合物具有一氧化氮合酶抑制活性，以及描述了制备和含有所述化合物的组合物的过程。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US20140235634A1

  公开（公告）日：2014-08-21

  Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.

  本文描述了公式（I）或公式（VI）的化合物，其药学上可接受的盐以及其药物组合物。还提供了包含公式（I）或公式（VI）化合物及其药物组合物的微粒（例如，纳米颗粒），这些微粒具有穿透黏液的特性。还提供了使用这些化合物或药物组合物治疗疾病的方法。
• [EN] COT MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE COT ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GILEAD SCIENCES INC

  公开号：WO2020252151A1

  公开（公告）日：2020-12-17

  The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) of generic Formula (I) and methods of use and manufacture thereof.

  本公开涉及一般性地与Cot（癌症大阪甲状腺）的通用化学式（I）的调节剂，以及其使用和制造方法。
• [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISO-INDOLINONE
  申请人：MONTE ROSA THERAPEUTICS

  公开号：WO2021069705A1

  公开（公告）日：2021-04-15

  Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.

  本公开涉及一种化合物或药用可接受盐或其立体异构体，其化学式为I，其中X1为直链或支链的C1-6烷基，C3-6环烷基，-C1-6烷基C3-6环烷基，C6-10芳基，5-10成员杂芳基，C1-6烷基C6-10芳基，C1-6烷基5-10成员杂芳基，其中X1未取代或取代为一个或多个卤素，直链或支链的C1-6烷基，直链或支链的C1-6杂烷基，CF3，CHF2，-O-CHF2，-O-(CH2)2-OMe，OCF3，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-OC(O)-C1-4烷基氨基，-C(O)O-C1-6烷基，-COOH，-CHO，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-6烷氧基或C1-6烷基羟基；X2为氢，C6-10芳基，5-10成员杂芳基，-O-(5-10成员杂芳基)，4-8成员杂环烷基，C1-4烷基4-8成员杂环烷基，-O-(4-8成员杂环烷基)，-O-C1-4烷基-(4-8成员杂环烷基)，-OC(O)-C1-4烷基-4-8成员杂环烷基或C6芳氧基，其中X2未取代或取代为一个或多个直链或支链的C1-6烷基，NH2，NMe2或5-6成员杂环烷基；n为0、1或2。
• Benzodiazepine derivatives
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05556969A1

  公开（公告）日：1996-09-17

  Compounds of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or specified optionally substituted alkyl, R.sup.2 is specified optionally substituted phenyl or pyridyl, x is 0, 1, 2 or 3, R.sup.3 is a specified alkyl, halo or amino and R.sup.4 is specified cycoalkyl or bicycloalkyl; and salts and prodrugs thereof, are useful as antagonists of cholecystokin and gastrin receptors.

  公式(I)的化合物：##STR1## 其中R1是氢或指定的可选取代烷基，R2是指定的可选取代苯基或吡啶基，x是0、1、2或3，R3是指定的烷基、卤素或氨基，R4是指定的环烷基或双环烷基；以及它们的盐和前药，可用作胆囊激肽和胃泌素受体的拮抗剂。